课题基金 / 基金详情

In vivo quantification of glutamatergic abnormalities in patients with Alzheimer's disease

In vivo quantification of glutamatergic abnormalities in patients with Alzheimer's disease
阿尔茨海默病患者谷氨酸能异常的体内定量
批准号：
225781
负责人：
Rosa-Neto Pedro
金额：
$46.02万
依托单位：
CIUSSS de l'Ouest-de-l'Ile-de-Montral-Douglas Hospital
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2011
资助国家：
加拿大
项目状态：
已结题
起止时间：
2011-03-01 至 2015-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=225781&lang=en
关键词：
Alzheimer'S Disease Amyloid-Beta Biomarkers Csf Imaging Pet

项目摘要

项目成果

Rosa-Neto Pedro的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Alzheimer's disease (AD) is the most common form of dementia after 65 years old. AD dementia is characterized by a silent period followed by a progressive deterioration of cognitive function. Loss of neuronal contacts, accumulation of abnormal proteins p
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Sex differences in brain tau aggregates.
In vivo quantification of tau aggregates as a measure of disease progression in Alzheimer's disease spectrum
In vivo quantification of tau aggregates as a measure of disease progression in Alzheimer's disease spectrum
Imaging epigenetics in dementia
海外基金